LGVN (Longeveron) FCF Margin % : -429.88% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Longeveron FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Longeveron's Free Cash Flow for the three months ended in Sep. 2024 was $-3.32 Mil. Longeveron's Revenue for the three months ended in Sep. 2024 was $0.77 Mil. Therefore, Longeveron's FCF Margin % for the quarter that ended in Sep. 2024 was -429.88%.

As of today, Longeveron's current FCF Yield % is -56.60%.

The historical rank and industry rank for Longeveron's FCF Margin % or its related term are showing as below:

LGVN' s FCF Margin % Range Over the Past 10 Years
Min: -2778 Med: -545.3 Max: -44.69
Current: -825.15

During the past 6 years, the highest FCF Margin % of Longeveron was -44.69%. The lowest was -2778.00%. And the median was -545.30%.

LGVN's FCF Margin % is ranked worse than
72.73% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs LGVN: -825.15

Longeveron FCF Margin % Historical Data

The historical data trend for Longeveron's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longeveron FCF Margin % Chart

Longeveron Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-44.69

-46.63

-838.13

-1,213.18

-2,778.00

Longeveron Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-3,114.00	-4,092.31	-571.72	-1,048.72	-429.88

Competitive Comparison of Longeveron's FCF Margin %

For the Biotechnology subindustry, Longeveron's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longeveron's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Longeveron's FCF Margin % falls into.

Longeveron FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Longeveron's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-19.696	/	0.709
	=	-2,778.00 %

Longeveron's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-3.323	/	0.773
	=	-429.88 %

Longeveron FCF Margin % Related Terms

Thank you for viewing the detailed overview of Longeveron's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Longeveron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136

Website

https://www.longeveron.com

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Executives

Khoso Baluch	director	1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Hashad Mohamed Wa'el Ahmed	officer: Chief Executive Officer	SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare	director, officer: Chief Scientific Officer	C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Cathy Ross	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Jeffrey Pfeffer	director
Lisa Locklear	officer: Chief Financial Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova	officer: Chief Medical Officer	1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo	officer: CFO and Treasurer	1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Kwan-hong Christopher Min	officer: Chief Medical Officer	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo	director	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green	officer: CEO	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr	officer: General Counsel, Secretary	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro	director	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer	director, 10 percent owner	1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136